Wendy Guy

CIK: 0001799360

Transaction Breakdown

Open Market Buys (P)7 (53.8%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (15.4%)

Derivative conversions

Awards (A)4 (30.8%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

PCSA

Processa Pharmaceuticals, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (13 total)

PCSA
Processa Pharmaceuticals, Inc.
Jul 26, 2026
Award(A)
Restricted Stock Units
Direct
9.5K shares-
PCSA
Processa Pharmaceuticals, Inc.
Jun 30, 2026
Purchase(P)
Direct
2.4K shares at avg. $1.93$5K
PCSA
Processa Pharmaceuticals, Inc.
Jun 15, 2026
Purchase(P)
Direct
2.1K shares at avg. $2.22$5K
PCSA
Processa Pharmaceuticals, Inc.
May 29, 2026
Purchase(P)
Direct
1.8K shares at avg. $2.57$5K
PCSA
Processa Pharmaceuticals, Inc.
May 15, 2026
Purchase(P)
Direct
1.6K shares at avg. $2.97$5K
PCSA
Processa Pharmaceuticals, Inc.
Apr 30, 2026
Purchase(P)
Direct
1.7K shares at avg. $2.69$5K
PCSA
Processa Pharmaceuticals, Inc.
Apr 15, 2026
Purchase(P)
Direct
1.6K shares at avg. $2.97$5K
PCSA
Processa Pharmaceuticals, Inc.
Mar 31, 2026
Purchase(P)
Direct
1.9K shares at avg. $2.54$5K
PCSA
Processa Pharmaceuticals, Inc.
Jan 1, 2026
Exercise(M)
Direct
193 shares-
PCSA
Processa Pharmaceuticals, Inc.
Oct 1, 2025
Award(A)
Restricted Stock Units
Direct
50K shares-
PCSA
Processa Pharmaceuticals, Inc.
Oct 1, 2025
Award(A)
Stock Options (Right to Buy)
Direct
150K shares-
PCSA
Processa Pharmaceuticals, Inc.
Jul 24, 2025
Award(A)
Restricted Stock Units
Direct
1.4M shares-
PCSA
Processa Pharmaceuticals, Inc.
Apr 1, 2025
Exercise(M)
Direct
14.5K shares-

		Type	Shares	Price		Ownership
Jul 26, 2026	PCSA Processa Pharmaceuticals, Inc.	Award(A) Restricted Stock Units	9,450	-	-	Direct
Jun 30, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	2,436	$1.93	$4,701	Direct
Jun 15, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	2,118	$2.22	$4,702	Direct
May 29, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	1,829	$2.57	$4,701	Direct
May 15, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	1,583	$2.97	$4,702	Direct
Apr 30, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	1,748	$2.69	$4,702	Direct
Apr 15, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	1,583	$2.97	$4,702	Direct
Mar 31, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	1,854	$2.54	$4,700	Direct
Jan 1, 2026	PCSA Processa Pharmaceuticals, Inc.	Exercise(M)	193	-	$0	Direct
Oct 1, 2025	PCSA Processa Pharmaceuticals, Inc.	Award(A) Restricted Stock Units	50,000	-	-	Direct
Oct 1, 2025	PCSA Processa Pharmaceuticals, Inc.	Award(A) Stock Options (Right to Buy)	150,000	-	-	Direct
Jul 24, 2025	PCSA Processa Pharmaceuticals, Inc.	Award(A) Restricted Stock Units	1,366,046	-	-	Direct
Apr 1, 2025	PCSA Processa Pharmaceuticals, Inc.	Exercise(M)	14,482	-	-	Direct

1-13 of 13 transactions

About Guy Wendy

Guy Wendy (SEC CIK 0001799360) files insider reports with the SEC as Chief Administrative Officer of Processa Pharmaceuticals, Inc. (PCSA).

Signal8 holds 13 ownership filings by Guy Wendy, all Form 4s, filed between Apr 11, 2025 and Jul 28, 2026. Those filings report 13 transactions, from Apr 1, 2025 to Jul 26, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Guy Wendy's filings is in VERO BEACH, FL.

Recent filings by Guy Wendy

Jul 26, 2026: Grant or award of PCSA derivative securities (Form 4, code A).
Jun 30, 2026: Open-market purchase of PCSA shares (Form 4, code P).
Jun 15, 2026: Open-market purchase of PCSA shares (Form 4, code P).
May 29, 2026: Open-market purchase of PCSA shares (Form 4, code P).
May 15, 2026: Open-market purchase of PCSA shares (Form 4, code P).

Other insiders filing for Processa Pharmaceuticals, Inc. (PCSA)

Ng George K, Chief Executive Officer
GUJRATHI SHEILA, Director
Yorke Justin W, Director
SKIBSTED RUSSELL, Chief Financial Officer
Pannu Geraldine, Director
Neal James R, Director

How to read Form 4 transaction codes